This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages) This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.Find sources: "OPKO Health" – news · newspapers · books · scholar · JSTOR (November 2023) (Learn how and when to remove this template message) This article relies excessively on references to primary sources. Please improve this article by adding secondary or tertiary sources. Find sources: "OPKO Health" – news · newspapers · books · scholar · JSTOR (March 2018) (Learn how and when to remove this template message) This article may need to be rewritten to comply with Wikipedia's quality standards. You can help. The talk page may contain suggestions. (November 2023) This article contains text that is written in a promotional tone. Please help improve it by removing promotional language and inappropriate external links, and by adding encyclopedic text written from a neutral point of view. (November 2023) (Learn how and when to remove this template message) (Learn how and when to remove this template message)
OPKO Health
Company typePublic
Nasdaq: OPK
Russell 2000 Component TASE: OPK
IndustryMedical Appliances & Equipment
Founded1991 Edit this on Wikidata
HeadquartersMiami, Florida
ProductsMedical Products
Number of employees
6,096[1]
Websitewww.opko.com

OPKO Health is a medical test and medication company focused on diagnostics and pharmaceuticals. The company is a publicly traded company on NASDAQ and TASE under the symbol "OPK".[2]

History

OPKO Health is a diversified healthcare company present in more than 30 countries. The company's primary businesses include:

The Chairman and CEO of OPKO is Dr. Phillip Frost, a billionaire biotech entrepreneur who previously held Chairman positions during the early stages and successful sales of Key Pharmaceuticals, Ivax Corporation, and Teva Pharmaceuticals.

In May 2022, OPKO Health announced the acquisition of U.S based Biotechnology firm, ModeX. The Acquisition worth $300 million saw OPKO gain proprietary immunotherapy technology with a focus on infectious diseases and Oncology, to focus on a range of cancers and infectious diseases, with applicability to other therapeutic areas.[3]

Products lines

Diagnostics: Bioreference Laboratory, 4k Test Score, Claros 1 Point of Care Diagnostic Platform Therapeutics: Vitamin D and Phosphate Management Products, Growth Hormone, Hemophilia and Obesity Products, Other Small Molecule and Biological Therapeutics, Vaccines Strategic Investments: ARNO Therapuetics, BioCardia, ChromaDex Corporation, Cocrystal Pharma, MABVAX, Neovasc, Pharmsynthez, RXi Pharmaceuticals, VBI Vaccines, Sevion, Xenetic Biosciences, Zebra Biologic

Litigation

On September 7, 2018, the SEC filed a lawsuit against a number of individuals and entities including Opko Health and the CEO and Chairman, Dr. Phillip Frost. In December 2018, the company and Dr. Frost entered into settlements with the SEC, which, upon approval by the court in January 2019, resolved the claims. Without admitting or denying any of the allegations, the company agreed to an injunction from violations of Section 13(d) of the “Exchange Act”, a strict liability claim, and to pay a $100,000 penalty, which has been paid.[4]
On March 8, 2019, the SEC filed an amended complaint, with OPKO paying $100,000 "Without admitting or denying the SEC's allegations."[5]

References

  1. ^ "OPKO's Competitors, Revenue, Number of Employees, Funding, Acquisitions & News - Owler Company Profile".
  2. ^ "Business Summary". Retrieved Dec 22, 2013.
  3. ^ "OPKO Health Acquires ModeX Therapeutics, Gains Proprietary Immunotherapy Technology with a Focus on Oncology and Infectious Diseases". Yahoo Finance. 9 May 2022. Retrieved 9 May 2022.
  4. ^ "Array Biopharma Annual Report (Form 10-K)". www.sec.gov. Securities and Exchange Commission. March 1, 2019.
  5. ^ "SEC Settles with Multiple Defendants in Market Manipulation Case and Amends Complaint as to Thirteen Remaining Defendants". U.S. Securities and Exchange Commission. Mar 22, 2019. Retrieved March 22, 2019.

External links

Categories